Abstract
<h3>Background</h3> Clinical data demonstrates increased antigen presentation diversity is a key factor in determining response rates to checkpoint inhibitors.<sup>1</sup> In addition to tumour mutational burden/microsatellite instability, increased HLA heterozygosity and...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have